Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · PT-141 (Bremelanotide)Weak / none
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
A medicinal-chemistry study designing and testing 14 new macrocyclic peptide analogues as selective ligands for human melanocortin receptors (MC1R, MC3R, MC4R, MC5R). PT-141 (bremelanotide) appears here only as context, cited alongside setmelanotide as a clinical-success example that motivates the macrocycle approach, not as a compound under study. Researchers reported that two new analogues emerged as potent, selective MC4R antagonists and one as a selective agonist, with structure-activity insights for the class. This is early discovery-stage, in-vitro receptor pharmacology; human data are needed before clinical conclusions can be drawn, and the new molecules are experimental, not PT-141. For readers following PT-141, the value is contextual: it situates bremelanotide within an active, credible drug-design field targeting these receptors for metabolic and inflammatory conditions, and underscores how selectivity between receptor subtypes drives both intended effects and side effects. It reports nothing new about PT-141's own efficacy or safety.
Journal of medicinal chemistryn=—In vitroJun 24, 2026 - Study · PT-141 (Bremelanotide)Weak / none
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Bremelanotide features here only as a worked example in a chemistry-and-history review of FDA-approved drugs built from D-amino acids — the mirror-image forms of the body's standard L-amino acids. It is not an efficacy study and says nothing new about whether the peptide works. Its value for readers is mechanistic context: D-amino-acid substitutions resist the proteases that rapidly degrade ordinary peptides, which is part of why engineered melanocortin peptides like bremelanotide are stable enough to be viable drugs. The review situates bremelanotide alongside desmopressin, leuprolide, and etelcalcetide as instances of this design strategy, enabled by solid-phase peptide synthesis and mirror-image phage display. Weight it as background on peptide drug design, not as clinical evidence. Nothing here speaks to bremelanotide's effect size, safety in any population, or its narrow FDA-approved indication.
Drug development researchn=——May 1, 2026 - Study · PT-141 (Bremelanotide)Mixed
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
This is a systematic review and meta-analysis — near the top of the evidence hierarchy — and one of the stronger pieces of context for bremelanotide in this set. From nearly 9,000 screened abstracts, 36 studies (26 RCTs) met criteria, and the authors pooled data for mindfulness-based CBT, flibanserin, and bremelanotide in women with desire, arousal, or orgasm dysfunction without sexual pain. For bremelanotide, they report statistically significant improvement in total Female Sexual Function Index scores and its desire and arousal subscales, plus reduced distress. Two caveats temper this. First, no study directly compared the peptide against psychotherapy, so relative benefit is unknown. Second, the meta-analysis inherits the modest effect sizes and heterogeneous, self-report endpoints of the underlying trials, which other authors have criticized. The finding is consistent with bremelanotide's approved profile: a real but modest, distress-reducing effect in a specific population, not a large or broadly generalizable one.
Journal of minimally invasive gynecologyn=—HumanJan 1, 2026 - Study · PT-141 (Bremelanotide)Weak / none
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
No abstract was available, so this note is based on the title alone and its findings are unknown. The article is a review posing the question of whether bremelanotide should be considered for sexual arousal and desire disorders in men — a framing, not a result. That framing matters because it sits outside the peptide's evidence base: bremelanotide is FDA-approved (as Vyleesi) only for acquired, generalized HSDD in premenopausal women. The male sexual-dysfunction data are earlier-stage and were never carried to a Phase III registration programme, so any male use is off-label and rests on thinner ground. Without the abstract we cannot say what evidence the authors marshal or what they conclude. Treat this as a signal that the question is being asked in the literature, not as support for male use. Readers should not infer efficacy or safety in men from a title.
Journal of clinical psychopharmacologyn=——Jan 1, 2026 - Study · PT-141 (Bremelanotide)Weak / none
Quantification of "Mercy Sex" in Heterosexual Women.
This is a methodological review, not a bremelanotide efficacy study — the peptide appears only because its Phase III trials supplied baseline data. Pooling published, placebo-controlled HSDD trials, the authors report that women with documented HSDD engaged in satisfying sexual events roughly 2.5 times per month at baseline, and argue this behaviour (which they term "mercy sex") could inflate placebo responses and blur the satisfying-sexual-event endpoint that anchored the bremelanotide and flibanserin programmes. Read it as a caution about how female sexual-desire trials are measured rather than as evidence about the peptide itself. It usefully reframes bremelanotide's modest reported effect sizes: if the primary endpoint is noisy at baseline, small drug-versus-placebo differences are harder to interpret. As a narrative synthesis with a convenience sample and a hypothesis-generating aim, it proves nothing about mechanism or benefit; it flags a design problem worth weighing when reading any HSDD efficacy claim.
Journal of sex & marital therapyn=——Jan 1, 2026 - Study · TirzepatideWeak / none
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026. The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies. The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis. For readers tracking investigational peptides: the review adds conceptual framing...
Frontiers in agingn=——Jan 1, 2026 - Study · PT-141 (Bremelanotide)Weak / none
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
This is a narrative clinical review of sexual health after breast and gynecologic cancer, and bremelanotide appears only briefly among options mentioned for low desire. The authors state that bremelanotide and flibanserin have shown efficacy for low desire, but the review does not present cancer-survivor-specific trial data for the peptide — that is an extrapolation from its premenopausal-HSDD approval to a population it was not tested in. That gap matters: cancer survivors often have distinct hormonal, vascular, and psychological drivers of sexual dysfunction, and safety or benefit in this group cannot be assumed from general HSDD trials. The review's more concrete guidance concerns non-hormonal measures (moisturizers, lubricants, dilators, pelvic-floor therapy) and cautions against vaginal lasers and compounded hormones in these patients. Weight the bremelanotide content as a passing mention within a synthesis that applied no formal quality-grading tool, not as evidence of benefit in survivors.
Journal of minimally invasive gynecologyn=——Dec 17, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.
This narrative review addresses menopausal hot flushes and low libido in breast-cancer patients on endocrine therapy, summarising newer agents including the libido drug bremelanotide, which is PT-141, a melanocortin-receptor agonist. Its central caveat is important: the pivotal trials of these libido agents excluded women with breast cancer, so their use in this population is extrapolation, not evidence. The review offers practical framing for clinicians rather than new data, and it does not report efficacy or safety outcomes specific to breast-cancer patients. For PT-141 readers, the useful signal is a boundary condition, the peptide's evidence base does not yet extend to breast-cancer survivors on endocrine therapy, and the authors approach its use in that group cautiously while awaiting research.
Expert review of clinical pharmacologyn=——Oct 1, 2025 - Study · Melanotan IWeak / none
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.
Bremelanotide is named here only as an example of an FDA-approved melanocortin-receptor agonist; the review's real subject is how genetic variation in melanocortin receptors (MC1R-MC5R) relates to inflammatory and other disease risk. It offers useful mechanistic context — bremelanotide acts on the same receptor family (chiefly MC3R/MC4R centrally, with MC1R activity explaining the skin-pigmentation effect seen in some trials) that also participates in immune regulation — but it presents no efficacy or safety data for the peptide and does not study it. The inflammatory-disease connections the authors draw (for atopic dermatitis, scleroderma, and others) largely concern other melanocortin ligands such as alpha-MSH analogs, dersimelagon, and afamelanotide, not bremelanotide. Read this as background on the biology of the receptor system bremelanotide targets, and as a reminder that melanocortin signalling is pleiotropic. It contributes nothing to how one should weight the peptide's approved indication.
Diseases (Basel, Switzerland)n=——Sep 16, 2025 - Study · SemaglutideWeak / none
A biodegradable suction patch for sustainable transbuccal peptide delivery.
This is a preclinical drug-delivery study, and bremelanotide and semaglutide are payloads used to test a device rather than the object of any efficacy question. The team built a biodegradable version of a bioinspired "suction patch" that sticks to the inner cheek to push peptides across the buccal lining — an attempt to avoid injections and gut degradation. In beagle dogs, semaglutide absorption was substantially better than the marketed tablet after a 10-minute application; bremelanotide reached about 26% of the bioavailability of a subcutaneous injection. Testing was ex vivo (porcine cheek tissue) and in animals, with no human data, so these are engineering and pharmacokinetic signals, not evidence of clinical benefit for either peptide's indication. The result says nothing about whether either drug works better delivered this way, only that meaningful amounts can cross the tissue. These are preclinical findings; human data are needed before clinical conclusions can be drawn about the delivery route.
Journal of controlled release : official journal of the Controlled Release Societyn=—AnimalAug 10, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
This is a mechanistic animal study, and notably a largely negative one — which makes it valuable. Using a female Syrian hamster model, researchers mapped where melanocortin MC3R/MC4R receptors sit in the brain's dopamine reward system and tested whether bremelanotide engages that circuit. They found MC4R messenger RNA concentrated in dopamine neurons of the ventral tegmental area, but neither a low nor a high dose of bremelanotide changed melanocortin-receptor expression, and the drug did not enhance sexual reward in a conditioned place-preference test. The authors conclude, consistent with rat work, that bremelanotide does not appear to act on the VTA-nucleus accumbens reward pathway. This tempers simple "it boosts sexual reward via dopamine" narratives and underscores how incompletely the peptide's central mechanism is understood despite its approval. As a rodent study it is a mechanistic signal only; it neither confirms nor refutes clinical benefit in women, and human data remain the arbiter.
Neuropharmacologyn=—AnimalApr 1, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.
PT-141 (bremelanotide) appears here in a narrative review of intravenous peptides and amino acids for erectile dysfunction, grouped with PnPP-19, L-arginine, and L-citrulline. This is a topic overview, not an efficacy trial, and it addresses ED in men — a use outside bremelanotide's female-HSDD approval where the human evidence is early-stage. The review's framing is mechanistic: PT-141 is described as acting through central nervous system pathways rather than on blood vessels like PDE5 inhibitors (sildenafil and similar), which is an accurate reflection of its melanocortin biology. Usefully, the authors do not overclaim; they state that large-scale clinical trials are still needed to establish safety, dosing, and any combination effects. Weight this as a reasonable map of an emerging area rather than as support for using PT-141 for ED. It adds no new trial data and leaves the male-ED evidence gap intact.
Expert opinion on pharmacotherapyn=——Apr 1, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Novel Pharmacologic Treatments of Female Sexual Dysfunction.
This is a short clinical review of medications for female sexual dysfunction, with bremelanotide named as one of two FDA-approved options for HSDD alongside flibanserin. The abstract is brief and offers no new data; its purpose is practical guidance for clinicians on diagnosis, patient selection, expectation-setting, and side-effect management. That orientation is worth noting — it frames bremelanotide within a shared-decision context rather than asserting strong efficacy, which fits the peptide's documented profile of modest, distress-reducing benefit in a specific population. The review also flags investigational combinations (Lorexys, testosterone regimens) that remain unapproved. There is nothing here to raise or lower one's read of bremelanotide's evidence; it is a mention within a clinician-facing overview. Readers should not infer effect sizes or comparative benefit from this summary, and off-label or combination use described as investigational carries correspondingly weaker support.
Clinical obstetrics and gynecologyn=——Mar 1, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.
This is a clinician-focused review of drug options for HSDD in premenopausal women, and it is usefully candid about bremelanotide's limits. The authors note that flibanserin and bremelanotide are the only FDA-approved agents for generalized acquired HSDD in this group (with bupropion and buspirone used off-label), but they explicitly caution about limited efficacy, potential adverse effects, and transparency issues in trial reporting. That balanced, even skeptical, framing aligns with the broader evidence: bremelanotide's benefit is real but modest and its endpoints have been questioned. The review contains no new data; it synthesizes 25 years of literature and product monographs to guide individualized care and calls for further research using more suitable clinical endpoints before wide adoption. Weight it as a measured, practice-oriented reminder that approval is not the same as strong efficacy, and that patient selection and honest expectation-setting matter as much as the choice of agent.
The Annals of pharmacotherapyn=——Feb 1, 2025 - Study · PT-141 (Bremelanotide)Weak / none
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.
This is a computer-modelling (in silico) screen, and bremelanotide surfaces only as one of several existing drugs that docking software ranked as a possible binder to a SARS-CoV-2 replication enzyme (RdRp). No cells, animals, or people were involved — the work is entirely simulated binding and molecular-dynamics calculations. That places it at the very bottom of the evidence hierarchy for any antiviral claim: computational hits frequently fail when tested in the lab. The authors themselves stress that experimental and preclinical validation is required before any clinical consideration. For bremelanotide specifically, there is no biological, let alone clinical, evidence here of antiviral activity, and nothing about this repurposing hypothesis relates to its actual approved use or its melanocortin mechanism. Treat it as a hypothesis-generating computational exercise only. These are preclinical, in silico findings; experimental and human data would be needed before any conclusions could be drawn.
Turkish journal of biology = Turk biyoloji dergisin=—In vitroJan 1, 2025 - Study · PT-141 (Bremelanotide)Weak / none
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.
This is an in-vitro cancer study exploring a repurposing idea entirely unrelated to bremelanotide's approved use. In human glioblastoma cell lines, bremelanotide reduced expression of survivin (a protein that helps cancer cells resist death) and triggered cell death at concentrations reported as non-toxic to normal human cells; blocking MC3R/MC4R abolished the effect, and forcing survivin expression rescued the cells — a reasonably coherent mechanistic chain. It also appeared to augment killing by the chemotherapies temozolomide and osimertinib. These are cell-culture findings only: no animal or human data, no pharmacokinetics showing the drug reaches brain tumors at active concentrations, and glioblastoma cell lines are an imperfect model. The signal is interesting and mechanistically specific, but it is early and should not be read as evidence that bremelanotide has any role in cancer. These are preclinical in-vitro findings; animal and human studies would be required before any clinical conclusions could be drawn.
Anticancer researchn=—In vitroSep 1, 2024 - Study · PT-141 (Bremelanotide)Mixed
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
This is a critical re-examination of bremelanotide's own pivotal evidence, and it is one of the most important items in this set for weighting the peptide. The authors scrutinize the efficacy measures from the Phase III RECONNECT trials and argue the primary instruments (the Female Sexual Function Index and its desire domain, and the FSDS-DAO distress scale) have, at best, questionable validity in women with HSDD. More pointedly, they report that 8 of 11 pre-registered clinicaltrials.gov efficacy outcomes had gone unpublished, and when they analyzed those, effect sizes ranged from nil to small, with several apparent benefits likely derived post-hoc. This is a methodological critique, not a new trial, and it does not allege the drug is harmful — but it directly challenges how impressive the approval-supporting results really are. Read alongside the trials themselves, it argues that bremelanotide's benefit is statistically modest and rests on outcome measures whose meaningfulness for these patients is unproven. It should meaningfully temper any strong efficacy reading.
Journal of sex researchn=——May 1, 2024